Expanding the repertoire of modified vaccinia Ankara-based vaccine vectors via genetic complementation strategies

PLoS ONE

Volumn 4, Issue 5, 2009, Pages

  Garber, David A ^a,b   O'Mara, Leigh A ^a   Zhao, Jun ^a   Gangadhara, Sailaja ^a   An, In Chul ^a   Feinberg, Mark B ^a,b,c  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; MODIFIED VACCINIA VIRUS ANKARA VECTOR; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS VECTOR; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; URACIL DNA GLYCOSIDASE; VIRUS ANTIBODY; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; GENETIC COMPLEMENTATION; IMMUNIZATION; MALE; MOUSE; NONHUMAN; RHESUS MONKEY; TRANSGENE; VACCINIA VIRUS; VIRUS GENE; ANIMAL; C57BL MOUSE; CHICK EMBRYO; CHICKEN; CYTOLOGY; DNA REPLICATION; FIBROBLAST; FLOW CYTOMETRY; GENE VECTOR; GENETICS; IMMUNOLOGY; MACACA; METABOLISM; PHYSIOLOGY; SERODIAGNOSIS; SOUTHERN BLOTTING; VIRUS REPLICATION;

MACACA; MACACA MULATTA; MUS; ORTHOPOXVIRUS; POXVIRIDAE; VACCINIA VIRUS ANKARA;

ANIMALS; ANTIBODIES, VIRAL; BLOTTING, SOUTHERN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHICK EMBRYO; CHICKENS; DNA REPLICATION; FEMALE; FIBROBLASTS; FLOW CYTOMETRY; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENETIC COMPLEMENTATION TEST; GENETIC VECTORS; HIV ANTIBODIES; IMMUNIZATION, SECONDARY; MACACA MULATTA; MALE; MICE; MICE, INBRED C57BL; NEUTRALIZATION TESTS; TRANSGENES; URACIL-DNA GLYCOSIDASE; VACCINIA VIRUS; VIRAL VACCINES; VIRUS REPLICATION;

EID: 65549092767     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005445     Document Type: Article

References (76)

1. Mayr A, Hochstein-Mintzel V, Stickl H (1975) Abstammung, eigenschaften und verwendung des attenuierten vaccinia-stammes MVA [Passage history, properties, and applicability of the attenuated vaccinia virus strain MVA]. Infection 3: 6-14.
2. Meyer H, Sutter G, Mayr A (1991) Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. Journal of General Virology 72: 1031-1038.
3. Antoine G, Scheiflinger F, Dorner F, Falkner FG (1998) The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244: 365-396.
4. Blanchard TJ, Alcami A, Andrea P, Smith GL (1998) Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. Journal of General Virology 79: 1159-1167.
5. Sutter G, Moss B (1992) Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proceedings of the National Academy of Sciences of the United States of America 89: 10847-10851.
6. Carroll MW, Moss B (1997) Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 238: 198-211.
7. Drexler I, Heller K, Wahren B, Erfle V, Sutter G (1998) Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol 79(Pt 2): 347-352.
8. Wyatt LS, Earl PL, Eller LA, Moss B (2004) Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci U S A 101: 4590-4595.
9. Stittelaar KJ, Kuiken T, de Swart RL, van Amerongen G, Vos HW, et al. (2001) Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 19: 3700-3709.
10. Parrino J, McCurdy LH, Larkin BD, Gordon IJ, Rucker SE, et al. (2007) Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naive and vaccinia-immune individuals. Vaccine 25: 1513-1525.
11. Mwau M, Cebere I, Sutton J, Chikoti P, Winstone N, et al. (2004) A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol 85: 911-919.
12. Vasan SS SJ, Chen Z, Hurley A, Than S, Adesanya P, Bunce C, Boaz M, Boyle R, Saeed E, Gardiner DF, Zaharatos GJ, Caskey M, Fang Q, Schmidt C, Huang Y, Seamons L, Ho M, Lombardo A, Gilmour J, Keefer MC, Fast P, Ho DD (2007) Cellular and Humoral Immunogenicity of ADMVA, a clade C/B MVA-based HIV-1 Candidate Vaccine, in Healthy Volunteers. Seattle, WA, USA.
13. Keefer MCE M, Ferrari G, Metch B, Panicali D, Cardinali M, Goepfert P, Kalichman A, Carter D, Barroso P, McElrath J, Weinhold K, Frey SE (2007) Safety and Immunogenicity of rMVA-HIV and rFowlpox(FPV)-HIV Vaccines, Alone or in Combination, in Healthy Vaccinia-Naive HIV-1 Negative Participants. Seattle, WA, USA.
14. Sandstrom EW B, Hejdeman B, Nilsson C, Brave A, Bratt G, Robb M, Cox J, VanCott T, Marovich M, Stout R, Said A, Bakari M, Pallangyo K, Moss B, Earl P, Michael N, Birx D, Mhalu F, Biberfeld G (2007) Improved Modes of Delivering a Safe and Highly Immunogenic Multigene Multiclade HIV-1 DNA Plasmid Vaccine Boosted with HIV-1 MVA. Seattle, WA, USA.
15. Goepfert PH C, Frey S, Blattner W, Wright P, Qin L, Wyatt L, Hural J, Cooper C, Cardinali M, Elizaga M, Bernie M, Robinson H (2007) HIV-1 DNA Prime Followed by Recombinant MVA Boost is Well Tolerated and Immunogenic when Administered to Healthy HIV-1 Seronnegative Adults in HVTN065. Seattle, WA, USA.
16. Harrer TH J, Meyer T, Baedeker N, Sobek V, Baeuerle M, Jaeger H, Helm M, Gorriahn D, Schneider L, Harrer E (2007) Therapeutic Vaccination with MVA-nef: a Randomized, Controlled phase II Study in 77 HIV-1 Infected Patients Followed by Structured HAART Interruption. Seattle, WA, USA.
17. Moorthy VS, Imoukhuede EB, Keating S, Pinder M, Webster D, et al. (2004) Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men. J Infect Dis 189: 2213-2219.
18. Moorthy VS, Imoukhuede EB, Milligan P, Bojang K, Keating S, et al. (2004) A Randomised, Double-Blind, Controlled Vaccine Efficacy Trial of DNA/MVA ME-TRAP Against Malaria Infection in Gambian Adults. Plos Med 1: e33.
19. McShane H, Pathan AA, Sander CR, Goonetilleke NP, Fletcher HA, et al. (2005) Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis (Edinb) 85: 47-52.
20. McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, et al. (2004) Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 10: 1240-1244.
21. Bory J-PL J, Brun J-L, Dalstein V, Baudin M (2006) In a Phase II Study with HPV16 CIN2/3 Patients, Transgene's TG4001 Induces Clinical Regression and HPV16 Transcription Inhibition. Paris, France.
22. Corona Gutierrez CM, Tinoco A, Navarro T, Contreras ML, Cortes RR, et al. (2004) Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther 15: 421-431.
23. Smith CL, Dunbar PR, Mirza F, Palmowski MJ, Shepherd D, et al. (2005) Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int J Cancer 113: 259-266.
24. Smith CL, Mirza F, Pasquetto V, Tscharke DC, Palmowski MJ, et al. (2005) Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara. J Immunol 175: 8431-8437.
25. Casimiro DR, Bett AJ, Fu TM, Davies ME, Tang A, et al. (2004) Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors. J Virol 78: 11434-11438.
26. Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, et al. (2002) Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415: 331-335.
27. Hirsch VM, Fuerst TR, Sutter G, Carroll MW, Yang LC, et al. (1996) Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J Virol 70: 3741-3752.
28. Guimaraes-Walker A, Mackie N, McMichael A, Weber J, McCormack S, et al. (2004) Priming with a candidate HIV-1 clade A DNA vaccine followed by booster with HIV-1 clade A MVA vaccine in volunteers at low risk of HIV infection. Lausanne, Switzerland.
29. Jaoko W, Omosa G, Bhatt K, Matu L, Ogutu H, et al. (2004) Safety and Immunogenicity of DNA and MVA HIVA vaccines in phase I HIV-1 vaccine trials in Nairobi, Kenya. Lausanne, Switzerland.
30. Gasteiger G, Kastenmuller W, Ljapoci R, Sutter G, Drexler I (2007) Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines. J Virol 81: 11925-11936.
31. Kastenmuller W, Gasteiger G, Gronau JH, Baier R, Ljapoci R, et al. (2007) Cross-competition of CD8+ T cells shapes the immunodominance hierarchy during boost vaccination. J Exp Med 204: 2187-2198.
32. Fischer MA, Tscharke DC, Donohue KB, Truckenmiller ME, Norbury CC (2007) Reduction of vector gene expression increases foreign antigen-specific CD8+ T-cell priming. J Gen Virol 88: 2378-2386.
33. Davies DH, Wyatt LS, Newman FK, Earl PL, Chun S, et al. (2008) Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax. J Virol 82: 652-663.
34. Nguyen LH, Knipe DM, Finberg RW (1992) Replication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection. J Virol 66: 7067-7072.
35. Farrell HE, McLean CS, Harley C, Efstathiou S, Inglis S, et al. (1994) Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted. J Virol 68: 927-932.
36. Brockman MA, Knipe DM (2002) Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity. J Virol 76: 3678-3687.
37. Murphy CG, Lucas WT, Means RE, Czajak S, Hale CL, et al. (2000) Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus. J Virol 74: 7745-7754.
38. Shiver JW, Emini EA (2004) Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med 55: 355-372.
39. Holzer GW, Remp G, Antoine G, Pfleiderer M, Enzersberger OM, et al. (1999) Highly efficient induction of protective immunity by a vaccinia virus vector defective in late gene expression. Journal of Virology 73: 4536-4542.
40. Schaefer-Klein J, Givol I, Barsov EV, Whitcomb JM, VanBrocklin M, et al. (1998) The EV-O-derived cell line DF-1 supports the efficient replication of avian leukosis-sarcoma viruses and vectors. Virology 248: 305-311.
41. Himly M, Foster DN, Bottoli I, Iacovoni JS, Vogt PK (1998) The DF-1 chicken fibroblast cell line: transformation induced by diverse oncogenes and cell death resulting from infection by avian leukosis viruses. Virology 248: 295-304.
42. Falkner FG, Moss B (1990) Transient dominant selection of recombinant vaccinia viruses. J Virol 64: 3108-3111.
43. Falkner FG, Moss B (1988) Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors. J Virol 62: 1849-1854.
44. Franke CA, Rice CM, Strauss JH, Hruby DE (1985) Neomycin resistance as a dominant selectable marker for selection and isolation of vaccinia virus recombinants. Molecular & Cellular Biology 5: 1918-1924.
45. Hansen SG, Cope TA, Hruby DE (2002) BiZyme: a novel fusion protein-mediating selection of vaccinia virus recombinants by fluorescence and antibiotic resistance. Biotechniques 32: 1178, 1180, 1182-1177.
46. Sanchez-Puig JM, Blasco R (2000) Puromycin resistance (pac) gene as a selectable marker in vaccinia virus. Gene 257: 57-65.
47. Carroll MW, Moss B (1995) E. coli beta-glucuronidase (GUS) as a marker for recombinant vaccinia viruses. Biotechniques 19: 352-354, 356.
48. Berdy J (1980) Bleomycin-Type Antibiotics. In: Berdy J, ed. Amino Acid and Peptide Antibiotics. Boca Raton: CRC Press. pp 459-497.
49. Calmels T, Parriche M, Durand H, Tiraby G (1991) High efficiency transformation of Tolypocladium geodes conidiospores to phleomycin resistance. Curr Genet 20: 309-314.
50. Stuart DT, Upton C, Higman MA, Niles EG, McFadden G (1993) A poxvirus-encoded uracil DNA glycosylase is essential for virus viability. J Virol 67: 2503-2512.
51. Millns AK, Carpenter MS, DeLange AM (1994) The vaccinia virus-encoded uracil DNA glycosylase has an essential role in viral DNA replication. Virology 198: 504-513.
52. Holzer GW, Falkner FG (1997) Construction of a vaccinia virus deficient in the essential DNA repair enzyme uracil DNA glycosylase by a complementing cell line. Journal of Virology 71: 4997-5002.
53. Ellison KS, Peng W, McFadden G (1996) Mutations in active-site residues of the uracil-DNA glycosylase encoded by vaccinia virus are incompatible with virus viability. J Virol 70: 7965-7973.
54. De Silva FS, Moss B (2003) Vaccinia virus uracil DNA glycosylase has an essential role in DNA synthesis that is independent of its glycosylase activity: catalytic site mutations reduce virulence but not virus replication in cultured cells. J Virol 77: 159-166.
55. Moutaftsi M, Peters B, Pasquetto V, Tscharke DC, Sidney J, et al. (2006) A consensus epitope prediction approach identifies the breadth of murine T(CD8+)-cell responses to vaccinia virus. Nat Biotechnol 24: 817-819.
56. Da Costa XJ, Morrison LA, Knipe DM (2001) Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection. Virology 288: 256-263.
57. Mayr A, Stickl H, Muller HK, Danner K, Singer H (1978) Der Pockenimpfstamm MVA: Marker, genetische Struktur, Erfahrungen mit der parenteralen Schutzimpfung und Verhalten im abwehrgeschwachten Organismus [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism]. Zentralblatt Fur Bakteriologie, Parasitenkunde, Infektionskrankheiten Und Hygiene - Erste Abteilung Originale - Reihe B: Hygiene, Betriebshygiene, Praventive Medizin 167: 375-390.
58. Holzer GW, Gritschenberger W, Mayrhofer JA, Wieser V, Dorner F, et al. (1998) Dominant host range selection of vaccinia recombinants by rescue of an essential gene. Virology 249: 160-166.
59. Lauvau G, Glaichenhaus N (2004) Mini-review: Presentation of pathogen-derived antigens in vivo. Eur J Immunol 34: 913-920.
60. Basta S, Chen W, Bennink JR, Yewdell JW (2002) Inhibitory effects of cytomegalovirus proteins US2 and US11 point to contributions from direct priming and cross-priming in induction of vaccinia virus-specific CD8(+) T cells. J Immunol 168: 5403-5408.
61. Shen X, Wong SB, Buck CB, Zhang J, Siliciano RF (2002) Direct priming and cross-priming contribute differentially to the induction of CD8+ CTL following exposure to vaccinia virus via different routes. J Immunol 169: 4222-4229.
62. Norbury CC, Malide D, Gibbs JS, Bennink JR, Yewdell JW (2002) Visualizing priming of virus-specific CD8+ T cells by infected dendritic cells in vivo. Nat Immunol 3: 265-271.
63. Engram J, Dunham R, Makedonas G, Vanderford T, Sumpter B, et al. Vaccine-Induced, SIV-specific CD8+ T cells Reduce Virus Replication but Do Not Protect from SIV Disease Progression. manuscript submitted.
64. Ober BT, Bruhl P, Schmidt M, Wieser V, Gritschenberger W, et al. (2002) Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara. J Virol 76: 7713-7723.
65. Coulibaly S, Bruhl P, Mayrhofer J, Schmid K, Gerencer M, et al. (2005) The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection. Virology 341: 91-101.
66. Edghill-Smith Y, Golding H, Manischewitz J, King LR, Scott D, et al. (2005) Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med 11: 740-747.
67. Garg S, Oran AE, Hon H, Jacob J (2004) The hybrid cytomegalovirus enhancer/chicken beta-actin promoter along with woodchuck hepatitis virus posttranscriptional regulatory element enhances the protective efficacy of DNA vaccines. J Immunol 173: 550-558.
68. Kozak M (1991) Structural features in eukaryotic mRNAs that modulate the initiation of translation. J Biol Chem 266: 19867-19870.
69. Sutter G, Wyatt LS, Foley PL, Bennink JR, Moss B (1994) A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 12: 1032-1040.
70. Yuen L, Moss B (1987) Oligonucleotide sequence signaling transcriptional termination of vaccinia virus early genes. Proc Natl Acad Sci U S A 84: 6417-6421.
71. Snaith MR, Murray JA, Boulter CA (1995) Multiple cloning sites carrying loxP and FRT recognition sites for the Cre and Flp site-specific recombinases. Gene 166: 173-174.
72. Current Protocols in Molecular Biology Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, et al. (1999) John Wiley & Sons, Inc.
73. Church GM, Gilbert W (1984) Genomic sequencing. Proc Natl Acad Sci U S A 81: 1991-1995.
74. Tscharke DC, Karupiah G, Zhou J, Palmore T, Irvine KR, et al. (2005) Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines. J Exp Med 201: 95-104.
75. Earl PL, Americo JL, Moss B (2003) Development and use of a vaccinia virus neutralization assay based on flow cytometric detection of green fluorescent protein. J Virol 77: 10684-10688.
76. Manischewitz J, King LR, Bleckwenn NA, Shiloach J, Taffs R, et al. (2003) Development of a novel vaccinia-neutralization assay based on reporter-gene expression. J Infect Dis 188: 440-448.